59 assets in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Therapeutic assets addressing Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ropeginterferon Alfa-2B Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (41)
sim1811-03 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Jiangsu Simcere Pharmaceutical Co., Ltd.	P1	CC (41)
dt-7012 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Assistance Publique - Hôpitaux de Paris	Early P1	C (39)
Nitrogen Mustard Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Case Comprehensive Cancer Center	N/A	D (30)
Apr-Td011 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Northwestern University	Early P1	NR ()
L19IL2/L19TNF Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Philogen S.p.A.	P2	NR ()

Showing 51 to 59 of 59 assets

PreviousPage 2 of 2Next